Glomerulonephritis

A Comprehensive Medical Guide to Glomerulonephritis

Comprehensive Introduction & Overview

Glomerulonephritis (GN) represents a diverse group of kidney diseases characterized by inflammation of the glomeruli, the intricate filtering units nestled within the renal cortex. These microscopic structures, composed of a tuft of capillaries (the glomerulus) encased in Bowman's capsule, are responsible for filtering waste products, excess water, and toxins from the blood while retaining essential proteins and cells. When the glomeruli become inflamed, their delicate filtration barrier is compromised, leading to a cascade of events that can profoundly impair kidney function.

The clinical manifestations of glomerulonephritis are highly variable, ranging from asymptomatic urinary abnormalities detected incidentally to rapidly progressive kidney failure requiring urgent intervention. GN is not a single disease but rather a syndrome encompassing numerous specific conditions, each with distinct etiologies, pathophysiological mechanisms, and prognoses. It can be a primary kidney disease, originating solely within the kidneys, or a secondary manifestation of a systemic illness affecting multiple organs, such as lupus or vasculitis. Understanding glomerulonephritis is paramount in nephrology, as it stands as a leading cause of both acute kidney injury (AKI) and chronic kidney disease (CKD), frequently progressing to end-stage renal disease (ESRD) necessitating dialysis or kidney transplantation. This guide aims to provide an exhaustive overview of glomerulonephritis, detailing its clinical definition, underlying mechanisms, diagnostic approaches, and long-term implications.

Deep-dive into Technical Specifications / Mechanisms

Clinical Definition

At its core, glomerulonephritis is defined histologically by inflammatory changes within the glomerulus. These changes can involve the endothelial cells lining the capillaries, the mesangial cells (support cells within the capillary tuft), the podocytes (specialized epithelial cells covering the capillaries), or the glomerular basement membrane (GBM). The inflammation disrupts the normal selective permeability of the filtration barrier, leading to the hallmark features of GN: hematuria (blood in urine) and proteinuria (protein in urine). The specific pattern of cellular proliferation, immune complex deposition, and basement membrane alterations observed on kidney biopsy dictates the precise pathological classification of GN.

Etiology (Causes)

The causes of glomerulonephritis are broadly categorized into primary and secondary forms:

• Primary Glomerulonephritis: These conditions originate within the kidney itself, without evidence of a systemic disease.

  • IgA Nephropathy (Berger's Disease): The most common primary GN worldwide, characterized by IgA immune complex deposition in the mesangium. Often presents with recurrent episodes of gross hematuria, typically following an upper respiratory or gastrointestinal infection.
  • Post-infectious Glomerulonephritis (PIGN): Most commonly post-streptococcal (PSGN), occurring after a streptococcal infection (e.g., strep throat, impetigo). Characterized by diffuse proliferative GN with subepithelial immune deposits.
  • Membranoproliferative Glomerulonephritis (MPGN) / C3 Glomerulopathy: A heterogeneous group characterized by mesangial and endothelial cell proliferation and thickening of the GBM. Often associated with complement pathway dysregulation.
  • Minimal Change Disease (MCD): A common cause of nephrotic syndrome in children, characterized by effacement of podocyte foot processes on electron microscopy, with minimal changes on light microscopy.
  • Focal Segmental Glomerulosclerosis (FSGS): Characterized by sclerosis (scarring) affecting some glomeruli (focal) and only parts of those glomeruli (segmental). Can be primary (idiopathic), genetic, or secondary to various conditions.
  • Membranous Nephropathy (MN): Characterized by diffuse thickening of the GBM due to subepithelial immune deposits. Often associated with antibodies against the phospholipase A2 receptor (PLA2R) in primary forms.
  • Rapidly Progressive Glomerulonephritis (RPGN): A severe syndrome characterized by a rapid decline in GFR (over days to weeks) with crescent formation on kidney biopsy. It can be:
    • Anti-GBM Disease (Goodpasture's Syndrome): Autoantibodies target the GBM.
    • Immune Complex-Mediated: Such as severe PSGN, lupus nephritis.
    • Pauci-immune: Associated with ANCA-positive vasculitis (e.g., Granulomatosis with Polyangiitis, Microscopic Polyangiitis).

• Secondary Glomerulonephritis: These are manifestations of systemic diseases that affect other organs in addition to the kidneys.

  • Systemic Lupus Erythematosus (SLE) / Lupus Nephritis: An autoimmune disease causing immune complex deposition in various glomerular compartments, classified into six distinct classes (I-VI) based on biopsy findings.
  • Vasculitis: Systemic inflammation of blood vessels.
    • ANCA-associated vasculitis: Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA). These are often pauci-immune RPGN.
    • Other vasculitides: Henoch-Schönlein Purpura (IgA vasculitis), Polyarteritis Nodosa.
  • Infections: HIV-associated nephropathy, Hepatitis B/C-associated GN, Endocarditis-associated GN.
  • Amyloidosis: Deposition of abnormal proteins (amyloid fibrils) in the glomeruli.
  • Diabetes Mellitus (Diabetic Nephropathy): While distinct pathologically (glomerular hypertrophy, mesangial expansion, GBM thickening), it is the most common cause of CKD and ESRD, and is often considered in the differential for kidney disease.
  • Paraneoplastic Syndromes: Certain cancers can induce GN.
  • Drugs: NSAIDs, gold, penicillamine can induce specific forms of GN.

Pathophysiology

The underlying mechanism of glomerular injury in GN is predominantly immune-mediated.
* Immune Complex Deposition: This is a common pathway. Circulating immune complexes (antigen-antibody complexes) can become trapped in the glomeruli, or antibodies can form in situ against antigens planted in the glomerulus or against intrinsic glomerular components (e.g., anti-GBM disease, PLA2R in membranous nephropathy). These immune complexes activate the complement system and recruit inflammatory cells (neutrophils, macrophages, T-lymphocytes), leading to direct tissue damage.
* Cell-Mediated Immunity: T-lymphocytes and macrophages directly infiltrate the glomeruli and release cytokines and chemokines, contributing to inflammation and structural damage. This is particularly relevant in pauci-immune vasculitis.
* Complement Activation: Regardless of the initial trigger, complement activation plays a central role in mediating inflammation and injury. Both classical and alternative pathways can be involved, leading to the formation of membrane attack complex (MAC) and recruitment of inflammatory cells.
* Structural Consequences:
* Proliferation: Increased number of glomerular cells (endothelial, mesangial, epithelial) narrows capillary lumens, impairing filtration.
* Sclerosis: Irreversible scarring of glomeruli, replacing functional tissue with fibrous material, leading to permanent loss of filtration capacity.
* Basement Membrane Thickening: Deposition of immune complexes or new GBM material can thicken the GBM, altering its permeability.
* Podocyte Injury: Damage to podocytes (e.g., effacement of foot processes) directly contributes to proteinuria.

These insults disrupt the glomerular filtration barrier, leading to increased permeability to proteins (proteinuria) and red blood cells (hematuria). Reduced glomerular filtration rate (GFR) leads to the retention of nitrogenous waste products (azotemia), fluid overload, and electrolyte disturbances. Activation of the renin-angiotensin-aldosterone system (RAAS) in response to kidney injury often contributes to systemic hypertension, further exacerbating kidney damage.

Clinical Staging/Grading

Unlike many cancers, glomerulonephritis does not have a single universal staging system. Instead, its severity and progression are assessed through several integrated measures:

• Histopathological Classification: The kidney biopsy is crucial for precise classification. Many forms of GN have their own specific grading or classification systems (e.g., Lupus Nephritis classes I-VI; IgA Nephropathy Oxford Classification MEST-C score). These systems describe the extent of glomerular, tubulointerstitial, and vascular damage, which directly correlates with prognosis and guides therapeutic decisions.
• Kidney Function (CKD Stages): The most common way to assess the functional impact is through the stages of Chronic Kidney Disease (CKD), based on the estimated Glomerular Filtration Rate (eGFR):
  • Stage 1: eGFR ≥ 90 mL/min/1.73 m² (with evidence of kidney damage, e.g., proteinuria).
  • Stage 2: eGFR 60-89 mL/min/1.73 m² (with evidence of kidney damage).
  • Stage 3: eGFR 30-59 mL/min/1.73 m².
  • Stage 4: eGFR 15-29 mL/min/1.73 m².
  • Stage 5: eGFR < 15 mL/min/1.73 m² (End-Stage Renal Disease).
• Proteinuria Levels: The amount of protein excreted in the urine (e.g., measured by 24-hour urine collection or urine protein-to-creatinine ratio) is a critical indicator of disease activity and predictor of progression. Massive proteinuria (>3.5 g/day) defines nephrotic syndrome.
• Clinical Course: GN can be classified by its temporal evolution:
  • Acute: Sudden onset, often self-limiting (e.g., PSGN).
  • Subacute/Rapidly Progressive: Rapid decline in kidney function over weeks to months (e.g., RPGN).
  • Chronic: Insidious onset, slow progression over years, often leading to CKD.

Extensive Clinical Indications & Usage

Standard Presentation (Signs and Symptoms)

The clinical presentation of glomerulonephritis is highly diverse and depends on the specific type, severity, and rate of progression. It can range from asymptomatic to life-threatening.

• Nephritic Syndrome: This is the classic presentation of acute glomerulonephritis, characterized by:
  • Hematuria: Gross (visible, "cola-colored" or smoky urine) or microscopic. Often accompanied by dysmorphic red blood cells and red blood cell casts on urinalysis, which are highly specific for glomerular bleeding.
  • Proteinuria: Usually in the non-nephrotic range (<3.5 g/day), but can be higher.
  • Hypertension: Due to fluid retention and activation of the RAAS.
  • Oliguria: Reduced urine output.
  • Edema: Swelling, typically periorbital (around the eyes) and peripheral (ankles, feet), due to fluid retention.
  • Azotemia: Elevated blood urea nitrogen (BUN) and creatinine, indicating reduced GFR.
• Nephrotic Syndrome: While often a distinct clinical entity, several forms of GN (e.g., Minimal Change Disease, Focal Segmental Glomerulosclerosis, Membranous Nephropathy) commonly present with nephrotic syndrome, characterized by:
  • Massive Proteinuria: >3.5 g/day.
  • Hypoalbuminemia: Low blood albumin levels due to urinary loss.
  • Severe Edema: Often generalized (anasarca), due to low oncotic pressure.
  • Hyperlipidemia: Elevated cholesterol and triglycerides.
  • Lipiduria: Lipids in the urine.
• Rapidly Progressive Glomerulonephritis (RPGN): A medical emergency presenting with a rapid decline in kidney function (eGFR drop >50% over weeks to months), often accompanied by severe nephritic features and systemic symptoms if part of a vasculitis.
• Asymptomatic Urinary Abnormalities: Many patients, especially with IgA nephropathy or early chronic GN, may only have microscopic hematuria and/or mild proteinuria detected incidentally on routine urinalysis.
• Chronic Glomerulonephritis: Develops insidiously over years, often presenting with non-specific symptoms of CKD such as fatigue, weakness, nausea, loss of appetite, pruritus, and persistent hypertension, before progressing to ESRD.

Differential Diagnosis

Distinguishing glomerulonephritis from other conditions affecting the kidneys or causing similar symptoms is critical for appropriate management.

Related Clinical Integration

In the clinical management of glomerulonephritis, a structured diagnostic and therapeutic approach is essential to preserve renal function and mitigate systemic inflammation. The diagnostic pathway typically begins with Kidney function tests (e.g., serum creatinine, BUN, urinalysis) / اختبارات وظائف الكلى (3095) (خدمات رعاية عامة) to assess glomerular filtration rate and identify hematuria or proteinuria, often followed by a Renal biopsy / خزعة الكلى (949e) (خدمات رعاية عامة) to confirm the specific histological subtype. Once diagnosed, immunosuppressive therapy is frequently initiated using Prednisone / بريدنيزون 5 mg to reduce acute inflammation, potentially supplemented by Cyclophosphamide / سيكلوفوسفاميد Standard in more aggressive or refractory cases. While these resources focus on nephrology, clinicians seeking broader professional development in related medical disciplines may refer to our specialized exam preparation materials, including Orthopedic Prometric MCQs - Chapter 3 Part 19, Orthopedic Prometric MCQs - Chapter 4 Part 11, Orthopedic Prometric MCQs - Chapter 4 Part 7, [ABOS Part I & AAOS OITE Comprehensive Orthopedic Review Questions | Part 22155](https://www.hutaifortho.com/en/hub/abos-part-i-comprehensive-review-batch-108/abos-part